AHCL · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 71/100 — Quality 74 · Valuation 68
| Share price | ₹15.00 |
| Market cap | ₹829 Cr |
| P/E ratio | 25.6 |
| P/B ratio | 3.1 |
| ROE | 53.6% |
| ROCE | 17.4% |
| Book value | ₹5.11 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹172 Cr | ₹29 Cr | 28.0% |
| 2025 | ₹120 Cr | ₹21 Cr | 27.0% |
| 2024 | ₹67 Cr | ₹10 Cr | 20.8% |
| 2023 | ₹113 Cr | ₹6 Cr | 9.8% |
| 2022 | — | — | — |
Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporate